The Food and Drug Administration (FDA) has announced that aprotinin (Trasylol) won't be available until officials complete a detailed review of it safety. The decision is based on early data from a terminated Canadian study suggesting an increased risk of death compared to two other antifibrinolytic drugs.
   In 2006, the FDA revised the labeling for Trasylol to strengthen its safety warning and limit its approved usage to patients at an increased risk for blood loss and blood transfusion during coronary bypass graft surgery. Because few treatment options exist for patients at risk for excessive bleeding during cardiac surgery, the FDA is working with the drug-maker to phase Trasylol out of the market without causing shortages of other drugs used for this purpose. Plus, FDA officials say they're committed to keeping Trasylol available for patients in whom potential benefits clearly outweigh risks.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins